Similarly, administration of a TLR3 agonist, ARNAX, with a tumor-associated antigen (TAA) enhanced anti-tumor immunity and sensitized ICB-resistant tumors to anti–PD-L1 therapy (185). Here, TLR3 is linked to neoplasm.